Kira Pharmaceuticals

Kira Pharmaceuticals company information, Employees & Contact Information

Kira Pharmaceuticals is a clinical-stage, global biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline of nine (9) novel complement assets focused on validated targets across the complement cascade. With an experienced team of complement biology experts, drug developers, protein engineers and leaders from across the pharma and biotech industry, Kira Pharmaceuticals is uniquely positioned to tackle some of the most complex and toughest challenges in the complement space and to deliver first-in-class and best-in-class therapies to transform the lives of patients. The company is headquartered in Cambridge, Massachusetts with offices in Suzhou and Shanghai, China, and Australia.

Company Details

Employees
23
Founded
-
Address
Cambridge, Ma, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, MA
Looking for a particular Kira Pharmaceuticals employee's phone or email?

Kira Pharmaceuticals Questions

News

Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies - PR Newswire

Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies PR Newswire

Kira Pharmaceuticals Appoints Teri Loxam as COO and CFO - citybiz

Kira Pharmaceuticals Appoints Teri Loxam as COO and CFO citybiz

Kira Pharma launches with $46M to bring complement drugs to more diseases - Fierce Biotech

Kira Pharma launches with $46M to bring complement drugs to more diseases Fierce Biotech

Kira Pharmaceuticals Presents Updated Data of Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH) at American Society of Hematology (ASH) 2024 Demonstrating Long-Term Safety and Efficacy - PR Newswire

Kira Pharmaceuticals Presents Updated Data of Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH) at American Society of Hematology (ASH) 2024 Demonstrating Long-Term Safety and Efficacy PR Newswire

Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations - 美通社

Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations 美通社

Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases - PR Newswire

Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases PR Newswire

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at European Hematology Association (EHA) Congress 2024 Demonstrating Long-term Safety and Efficacy - PR Newswire

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at European Hematology Association (EHA) Congress 2024 Demonstrating Long-term Safety and Efficacy PR Newswire

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Study in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2023 ASH Annual Meeting - PR Newswire

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Study in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2023 ASH Annual Meeting PR Newswire

Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA) - PR Newswire

Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA) PR Newswire

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia - PR Newswire

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia PR Newswire

Top Kira Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant